BioChaperone Lispro Exenatide (insulin lispro/exenatide) / Adocia - LARVOL DELTA

ExeQOL: Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients (clinicaltrials.gov) - P2/3; N=64; Completed; Sponsor: Centre Hospitalier Universitaire de Besancon; Recruiting ➔ Completed; N=544 ➔ 64

Clinical • Enrollment change • HEOR • Trial completion • Cardiovascular • Congestive Heart Failure

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (clinicaltrials.gov) - P3; N=120; Recruiting; Sponsor: Mount Sinai Hospital, Canada; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease. (PubMed, Am J Nephrol) - "Exenatide plus insulin glargine treatment for 24 weeks resulted in a reduction of albuminuria in T2DM patients with DKD."

Clinical • Journal • Cardiovascular • Diabetes • Diabetic Nephropathy • Gastrointestinal Disorder • Hypoglycemia • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus

Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL) (clinicaltrials.gov) - P3; N=120; Recruiting; Sponsor: Mount Sinai Hospital, Canada; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020

Trial completion date • Trial primary completion date